Drugs / Xenon

Trials 31 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06945614 Apr → Dec 2025 overdue General Biophysics LLC Recruiting No outcome recorded
Phase 1 NCT01043419 Jan → Mar 2010 sympathetic nervous system disorder Air Liquide Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07435103 Mar 2026 → Mar 2027 expected autism The Children's Hospital of Zhejiang University School of Medicine Not yet recruiting No outcome recorded
Phase 1/2 NCT01545271 May 2012 → Oct 2013 brain hypoxia - ischemia University Hospitals Bristol and Weston NHS Foundation Trust Completed No outcome recorded
Phase 28 trials
Phase 2 NCT04696523 Apr 2025 → Dec 2029 expected acquired aneurysmal subarachnoid hemorrhage, brain injury, brain ischemia, cerebral infarction +1 Turku University Hospital Recruiting No outcome recorded
Phase 2 NCT02768727 Apr 2016 → Dec 2019 cognitive disorder University of Pennsylvania Completed No outcome recorded
Phase 2 NCT02071394 Mar 2014 → Oct 2019 brain hypoxia - ischemia University Hospitals Bristol and Weston NHS Foundation Trust Completed No outcome recorded
Phase 2 NCT02098148 Nov 2013 → Jan 2014 obsessive-compulsive disorder Mclean Hospital Withdrawn No outcome recorded
Phase 2 NCT01757106 Dec 2012 → Jul 2013 coronary artery disorder Universitaire Ziekenhuizen KU Leuven Completed No outcome recorded
Phase 2 NCT01696630 Oct 2012 → Jul 2014 colorectal cancer Centre Leon Berard Completed No outcome recorded
Phase 2 NCT01262729 Sep 2011 → Nov 2014 cardiac arrest RWTH Aachen University Terminated No outcome recorded
Phase 2 NCT01199276 Sep 2010 → Oct 2014 delirium Air Liquide Completed No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT04432155 Jun → Nov 2021 panic disorder Nobilis Therapeutics Inc. Unknown No outcome recorded
Phase 2/3 NCT03635827 Jun 2021 post-traumatic stress disorder Nobilis Therapeutics Inc. Unknown No outcome recorded
Phase 39 trials
Phase 3 NCT03176186 Mar 2026 → Apr 2029 expected post-cardiac arrest syndrome Invero Pharma, Inc. Not yet recruiting No outcome recorded
Phase 3 NCT05335109 Jan 2022 → Jan 2024 ischemic stroke Negovsky Reanimatology Research Institute Completed No outcome recorded
Phase 3 NCT02129400 May 2014 → Jan 2015 RWTH Aachen University Terminated No outcome recorded
Phase 3 NCT01839084 Jul 2013 → Feb 2016 RWTH Aachen University Completed No outcome recorded
Phase 3 NCT01285271 May → Sep 2011 coronary artery disorder RWTH Aachen University Completed No outcome recorded
Phase 3 NCT01294163 Apr 2011 → Apr 2014 coronary artery disorder, drug allergy Air Liquide Completed No outcome recorded
Phase 3 NCT01120405 May 2010 → Jul 2012 coronary artery disorder Air Liquide Completed No outcome recorded
Phase 3 NCT00919126 Jun 2009 → Jan 2012 Air Liquide SA Terminated No outcome recorded
Phase 3 NCT00192959 Mar → Dec 2004 Rigshospitalet, Denmark Completed No outcome recorded
Phase 45 trials
Phase 4 NCT03504033 Apr 2018 → Sep 2019 RWTH Aachen University Withdrawn No outcome recorded
Phase 4 NCT02682758 Feb → Mar 2016 Heinrich-Heine University, Duesseldorf Completed No outcome recorded
Phase 4 NCT01167803 Dec 2010 → Nov 2012 obesity disorder Nîmes University Hospital Completed No outcome recorded
Phase 4 NCT00937807 Jul 2009 → Feb 2010 Air Liquide Completed No outcome recorded
Phase 4 NCT00793663 Nov 2008 → Apr 2011 RWTH Aachen University Completed No outcome recorded
Phase not applicable3 trials
NCT02774096 Feb 2016 → Jul 2018 aortic disorder Beijing Anzhen Hospital Unknown No outcome recorded
NCT02468531 Jan 2015 → Jul 2017 acute lung injury Beijing Anzhen Hospital Unknown No outcome recorded
NCT01404819 Apr 2012 → Feb 2015 Nîmes University Hospital Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT06080100 Comparator Nov 2023 → Jan 2026 overdue anxiety The S.N. Fyodorov Eye Microsurgery State Institution Recruiting No outcome recorded
Phase 0 NCT03748446 Comparator Dec 2019 → Sep 2026 expected bipolar depression, major depressive disorder Massachusetts General Hospital Active not recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT01948765 Comparator Jun 2013 → Sep 2014 coronary artery disorder Universitaire Ziekenhuizen KU Leuven Completed No outcome recorded
Phase 2 NCT00879892 Comparator May 2009 → Sep 2014 brain ischemia Turku University Hospital Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 36 sources stand behind the page.

FieldValueCited text
Known as Xenon Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care” NCT04696523
34

NCT01948765

NCT00879892

NCT06945614

NCT01120405

NCT01696630

NCT00192959

NCT03504033

NCT04432155

NCT01839084

NCT02071394

NCT02098148

NCT05335109

NCT00793663

NCT01262729

NCT01043419

NCT01757106

NCT01294163

NCT03748446

NCT03176186

NCT01545271

NCT03635827

NCT02774096

NCT06080100

NCT02768727

NCT01199276

NCT00937807

NCT01285271

NCT02468531

NCT07435103

NCT01167803

NCT02129400

NCT00919126

NCT01404819

NCT02682758

Known as LENOXe “Hemodynamic Stability During Carotid Endarterectomy.Comparison of LENOXe™ (Xenon 100% v/v) Versus Sevoflurane” NCT00937807
1

“Security under LENOXe™ (xénon 100 % v/v) anesthesia” NCT01043419

Action Inhibit “In vitro, Xe decreases the uptake of NE in neuronal cells by the inhibition of NET.” PMID 22945969 Sep 2012
Modality Other / unclassified “The N-methyl-d-aspartate (NMDA) receptor (NMDA-R) antagonist xenon (Xe) induces general anaesthesia” PMID 22945969 Sep 2012
Route Inhaled inhaled xenon” NCT00192959